| Authors: |
Doedens JR; Resolve Therapeutics, LLC, Seattle, WA 98103;, Jones WD; EA Genomics/Q Solutions, Durham, NC 27703;, Hill K; PlasmaLab International, Everett, WA 98201;, Mason MJ; Sage Bionetworks, Seattle, WA 98109;, Gersuk VH; Benaroya Research Institute, Seattle, WA 98101;, Mease PJ; Swedish Medical Center and University of Washington, Seattle, WA 98122;, Dall'Era M; University of California, San Francisco, San Francisco, CA 94143;, Aranow C; The Feinstein Institute for Medical Research, Manhasset, NY 11030;, Martin RW; College of Human Medicine, Michigan State University, East Lansing, MI 48824;, Cohen SB; Metroplex Clinical Research Center, Dallas, TX 75231;, Fleischmann RM; Metroplex Clinical Research Center, Dallas, TX 75231;, Kivitz AJ; Altoona Center for Clinical Research, Duncansville, PA 16635;, Burge DJ; Resolve Therapeutics, LLC, Seattle, WA 98103;, Chaussabel D; Benaroya Research Institute, Seattle, WA 98101; Sidra Medical and Research Center, Doha, Qatar; and., Elkon KB; Department of Rheumatology, University of Washington, Seattle, WA 98109., Posada JA; Resolve Therapeutics, LLC, Seattle, WA 98103; jp@resolvebio.com. |